The global partner diagnostics (CD) market will reach 3.5 billion US dollars in 2020

Source: Biovalley 2014-6-12 companion diagnostic (CD) is an in vitro diagnostic technology, which can provide information about the treatment response of patients to specific treatment drugs, help to identify the patient groups who can benefit from a certain treatment product, so as to improve the treatment prognosis and reduce health care costs In addition, partner diagnosis helps to identify the population of patients most likely to respond to treatment drugs At present, partner diagnosis market is still in its infancy According to a recent report released by Allied Market Research (AMR), the global partner diagnosis (CD) market is worth US $1.1 billion in 2013 In the next seven years, the market will grow at a CAGR of 20% and reach US $3.5 billion in 2020 Geographically, the global partner diagnosis market can be divided into North America, Europe, Asia Pacific, lamea (Latin America, Middle East, Africa) North America has the largest market share (43.97%) in the middle of 2013, followed by Europe (38%) The 2 regions are the highest areas where partners earn the highest income They will continue to maintain their leading position until 2020, mainly due to the increase in incidence rate of cancer and other diseases in these areas and the higher awareness of health care Lamea is expected to be the fastest growing market with a CAGR of 22.7% over the forecast period Factors driving the growth of the global partner Diagnostics Market include the discovery of more and more biomarkers and the joint development of drugs and corresponding diagnostic kits However, the increasing cost of drug research and development may hinder the growth of the market From the perspective of indications, partner diagnosis market can be divided into oncology, cardiovascular disease, central nervous system, inflammation and virology Among them, oncology is the disease field with the highest income in partner diagnosis market At present, a variety of partner diagnosis kits have been developed for the detection of various cancer biomarkers The main driving force of this market segment is the growth of targeted drug development, which requires the development of corresponding partner diagnosis kits In terms of technology, partner diagnosis market can be divided into immunohistochemistry and molecular diagnosis Among them, molecular diagnosis will become the fastest growing and highest income generating field, mainly due to the widespread use of real-time PCR, in situ hybridization and new generation sequencing technology Other factors driving market growth, including advances in molecular diagnostic technology, have resulted in more accurate and accurate diagnostic results, while the application of these methods has also reduced the cost of detection Partner diagnosis is an emerging market According to the survey, most enterprises in this field are cooperating with pharmaceutical companies to develop partner diagnostic kits for their pipeline drugs Major players in the market include Dako (Agilent Technology), Qiagen, Roche, Abbott, Ventana medical, bioMerieux, Myriad Genetics, resonance health, Leica microsystems and life technologies Partner diagnosis is an important aspect of personalized treatment, which is very important to predict the response of patients to specific drugs With the increasing awareness of the public and the increasing incidence rate of cancer, companion diagnosis will become an important factor in targeted therapy At present, more and more companies are developing targeted therapy products Accordingly, the development of partner diagnostic kits has become an important part of their new drug development strategy (bio Com) original English: Global companion diagnostic (CD) market is expected to reach $3.5 billion by 2020 - Allied Market Research